Margaret F Prescott

US Patent:

20050020614, Jan 27, 2005

Filed:

Jan 9, 2003

Appl. No.:

10/501210

Inventors:

Margaret Prescott - Millburn NJ, US
Walter Schuler - Grenzach-Wyhlen, DE

International Classification:

A61K031/4745

US Classification:

514291000

Abstract:

Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.

US Patent:

20050209244, Sep 22, 2005

Filed:

Feb 27, 2003

Appl. No.:

10/505398

Inventors:

Margaret Prescott - Millburn NJ, US
David Feldman - Teaneck NJ, US

International Classification:

A61K031/506
A61F002/00

US Classification:

514252180, 424423000

Abstract:

The invention relates to the local administration of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt or crystal form thereof, optionally in conjunction with one or more other active ingredients, and a device adapted for such local administration.

US Patent:

20060013852, Jan 19, 2006

Filed:

Jun 27, 2003

Appl. No.:

10/519070

Inventors:

Margaret Prescott - Millburn NJ, US

International Classification:

A61K 31/445
A61K 31/4184
A61K 31/165

US Classification:

424423000, 514317000, 514381000, 514616000

Abstract:

The present invention relates to drug delivery systems, comprising an ARB or a RI, or at least two representatives selected from the group consisting of an ARB, an ACEI and a RI, or, in each case, a pharmaceutically acceptable salt thereof, for the prevention and treatment of proliferative diseases, particularly vascular diseases. The invention furthermore relates to the use of such drug delivery systems, for preventing or treating restenosis in diabetic and non-diabetic patients, or for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter in a subject in need thereof.

US Patent:

20060035879, Feb 16, 2006

Filed:

Nov 14, 2003

Appl. No.:

10/534790

Inventors:

Margaret Prescott - Millburn NJ, US

International Classification:

A61K 31/33
A61M 31/00

US Classification:

514183000, 424423000, 604500000

Abstract:

A drug delivery device or system comprising: a) a medical device, e.g. a coated stent or stent-graft, adapted for local application or administration in hollow tubes; and in conjunction therewith, b) a therapeutic dosage of an anti-inflammatory ascomycin derivative, such as pimecrolimus, e.g. affixed to the medical device, and use thereof in the preparation of a medicament for the prevention and treatment of inflammatory complications following vascular injury, and method of treatment therewith.

US Patent:

20060062823, Mar 23, 2006

Filed:

Dec 8, 2003

Appl. No.:

10/535879

Inventors:

Margaret Prescott - Morris Plains NJ, US

International Classification:

A61K 31/427
A61F 2/00

US Classification:

424423000, 514365000

Abstract:

A drug delivery device or system comprising: a) a medical device, e.g. a coated stent, adapted for local application or administration in hollow tubes; and, in conjunction therewith, b) a therapeutic dosage of a MIA, e.g. epothilone B, e.g. affixed to the medical device, and corresponding use in the preparation of a medicament, and corresponding method of treatment.

US Patent:

20060127440, Jun 15, 2006

Filed:

Feb 13, 2006

Appl. No.:

11/352767

Inventors:

Margaret Prescott - Millburn NJ, US

International Classification:

A61K 31/4745
A61F 2/06

US Classification:

424422000, 514291000, 623001110

Abstract:

Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.

US Patent:

20060166937, Jul 27, 2006

Filed:

Oct 14, 2003

Appl. No.:

10/531677

Inventors:

Margaret Prescott - Morris Plains NJ, US

International Classification:

A61K 31/675
A61K 31/663

US Classification:

514089000, 514102000

Abstract:

A method for the treatment of atherosclerosis, in particular atherosclerotic/valve calcification and plaque rupture/stroke, in a patient in need of such treatment, e.g. a patient with aterial or valve calcification, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient. Especially the invention relates to the local administration the bisphosphonate and to a device, e.g. stent adapted for such local administration.

US Patent:

20080161321, Jul 3, 2008

Filed:

Mar 16, 2005

Appl. No.:

10/592973

Inventors:

David Louis Feldman - Teaneck NJ, US
Steven Zelenkofske - Center Valley PA, US
Michaela Dinboeck - Basel, CH
Margaret Forney Prescott - Morris Plains NJ, US

International Classification:

A61K 31/496
A61K 31/165
A61P 3/10
A61P 9/12
A61P 9/00
A61P 3/00

US Classification:

51425218, 514616

Abstract:

The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, PVD including PAD and peripheral venous disorders, CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), AF, renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, AIN, ATN, acute tubulo-interstitial nephritis, PKD, vascular inflammation, rennin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with another active ingredient.